NAMSW NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM)
- 9.730
- +0.100+1.04%
NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) News
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
We are privileged to welcome Juliette to our management team as CBO," said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam.
ANGI, MLKN and KOD Are Among After Hour Movers
NewAmsterdam Pharma to Present New Analysis From the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination With Ezetimibe at 2024 American College of Cardiology Congress
NAARDEN, the Netherlands and MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical co
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients With HeFH And/or ASCVD
-- TANDEM is designed to evaluate obicetrapib and ezetimibe fixed-dose combination ("FDC") as an adjunct to diet and maximally tolerated lipid lowering therapy in patients with HeFH, ASCVD or ASCVD ri
NewAmsterdam Pharma Full Year 2023 Earnings: Revenues Miss Expectations
NewAmsterdam Pharma Co NV (NAMS) Faces Net Loss in 2023 Despite Clinical Progress
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
NAARDEN, The Netherlands and MIAMI, Feb. 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical com
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
NAARDEN, the Netherlands and MIAMI, Feb. 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of Its Board of Directors
NAARDEN, The Netherlands and MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a clinical-stage biopharmaceutical company d
NewAmsterdam Pharma Announces 2024 Strategic Priorities
-- Positioned for three Phase 3 trial readouts over the next 18 months -- -- Topline data expected from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and BROADWAY trial in ASCVD in 4Q 2024 -- -- Plan to i
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
-- BROADWAY Phase 3 trial enrollment completed; on-track to report topline data for Phase 3 BROOKLYN and BROADWAY trials in 2H 2024 – -- Announced initial data from Phase 2a clinical trial evaluating obicetrapib in
NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
NAARDEN, the Netherlands and MIAMI, Oct. 23, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a clinical-stage biopharmaceutical company d
NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam Pharma" or the "Company"), a clinical-stage biopharmaceutical c
NewAmsterdam Pharma Announces Appointment of William "BJ" Jones, Formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
NAARDEN, The Netherlands and MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of William "BJ" Jones as the Company's first Chief Commercial Officer ("CCO"), effective August 14, 2023. Mr. Jones brings 30 years of commercial and launch experience in the U.S. and globally, with particular experience in driving mass market product launch strategies for industry-leading brands. At NewAmsterdam, he will build and lead all commercial functions, including marketing, market access, sales, medical science engagement and commercial operations.
NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares
NAARDEN, The Netherlands and MIAMI, June 09, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS, "NewAmsterdam" or the "Company")), a clinical-stage biopharmaceutical company developing oral,
NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares
NAARDEN, The Netherlands and MIAMI, June 06, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; "NewAmsterdam" or the "Company"), a clinical-stage biopharmaceutical company dev
NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares
NAARDEN, the Netherlands and MIAMI, June 06, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS, "NewAmsterdam" or the "Company")), a clinical-stage biopharmaceutical company developing oral,
NewAmsterdam Pharma Announces Positive Topline Results From Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients
-- Achieved Primary Endpoint with Statistically Significant 45.8% Median Reduction in LDL-C (p < 0.0001) in patients treated with 10mg obicetrapib-- -- 29.7% Median Reduction in Apo B and 37.0% Median
NewAmsterdam Pharma Presents Full Data From Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination With Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
– Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p<0.0001) – – 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of <55 mg/dL com
NewAmsterdam Pharma to Present at Jefferies Healthcare Conference
NAARDEN, the Netherlands and MIAMI, May 31, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam Pharma" or the "Company"), a clinical-stage company focused on th
Analysis
Price Target
No Data
